Skip to main content

Advertisement

Table 3 Efficacy of the quadrivalent vaccine in preventing external genital lesions and AIN (per-protocol population)

From: Rome consensus conference - statement; human papilloma virus diseases in males

  Giuliano [67] Palefsky [71] Goldstone [72]
Population Per-protocol Per-protocol Per-protocol*
(16–26 years) (16–26 years) (16–26 years)
External genital lesions 90.4%;   
(95%; CI: 69.2–98.1)
AIN   77.5%; 91.7%;
(95%; CI: 39.6–93.3) (95%; CI: 44.6–99.8)
Anogenital warts 89.4%;   
  (95%; CI: 65.5–97.9)   
  1. * Post-hoc analysis. AIN Anal intraepithelial neoplasia.